National and Kapodistrian University of Athens
Σχεδιασμός καινοτόμων βιοδραστικών μορίων με τη βοήθεια της μοριακής προσομοίωσης για την αντιμετώπιση των εκφυλιστικών νόσων του Κ.Ν.Σ: alzheimer και parkinson
Abstract
dc:descriptionThe aim of this dissertation is the in silico rational design of new compounds against Alzheimer's and Parkinson diseases.The aspartic protease BACE-1 is a therapeutic target for Alzheimer's disease. Therefore, a series of 11 resveratrol derivatives and 11 glyoxylato-aroylhydrazones were studied against BACE-1. Initially, we studied their ability to penetrate the blood brain barrier (BBB) and be absorbed by the cells of the intestine epithelium Caco2. Furthermore, molecular docking calculations were performed in the active site of BACE-1. The results were promising and the compounds were biologically evaluated against the enzyme. Resveratrol and four derivatives of resveratrol showed significant inhibitory activity. The remaining derivatives were inactive. The glyoxylato-aroylhydrazones showed no significant inhibitory activity. These derivatives were also studied for their suppress the induction of cell death due to oxidative stress of HT22 cells. The comparison of the results of these two biological tests reveals that the activity of these compounds may be dual: first act as BACE-1 inhibitors and second protect nerve cells from oxidative death. Experiments on Differential Scanning Calorimetry and Molecular Dynamics techniques showed that the most active compounds exert stronger thermal effects.One of the classes of drugs used to treat Parkinson's disease is the monoamine oxidase type B (MAO-B). Literature studies support the inhibitory activity of coumarins against MAO-B. Thus, a series of 13 coumarin derivatives was studied. Initially, we evaluated the pharmacokinetic properties of the compounds and then we applied molecular docking in the active site of MAO-B. The results from both studies are encouraging and the compounds are under biological evaluation.AT1 antagonists exert antioxidant effects and may have beneficial effects in Alzheimer’s disease. For this reason, we investigated a possible activity of the synthetic analogue BV6 against BACE-1 using molecular docking studies. The results are promising and BV6 will be shortly biologically evaluated.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2014
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Koukoulitsa, Aikaterini
- Κουκουλίτσα, Αικατερίνη
Subjects
dc:subject × 18- Ορθολογικός σχεδιασμός
- Εκτίμηση φαρμακοκινητικών ιδιοτήτων
- Μοριακή μοντελοποίηση
- Μοριακή πρόσδεση
- Προσομοιώσεις μοριακής δυναμικής
- Rational design
- in silico evaluation of pharmacokinetic properties
- Molecular modeling
- Molecular docking
- Molecular dynamics simulations
- Φυσικές Επιστήμες
- Χημεία
- Ιατρική και Επιστήμες Υγείας
- Επιστήμες Υγείας
- Natural Sciences
- Chemical Sciences
- Medical and Health Sciences
- Health Sciences
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/42578